Indications for intervention during active surveillance of prostate cancer: A comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols

BJU International

Volumn 115, Issue 2, 2015, Pages 216-222

  Kates, Max ^a   Tosoian, Jeffrey J ^a   Trock, Bruce J ^a   Feng, Zhaoyong ^a   Carter, H Ballentine ^a   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

active surveillance; prostate biopsy; prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER THERAPY; CLINICAL PROTOCOL; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR VOLUME; ADVERSE EFFECTS; BIOPSY; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; HEALTH SURVEY; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UNITED STATES; WATCHFUL WAITING;

BIOPSY; CLINICAL PROTOCOLS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UNITED STATES; WATCHFUL WAITING;

EID: 84921526102     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12828     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-19
3. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012; 157: 120-134
4. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419-426
5. Klotz L,. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23: 8165-8169
6. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 228-234
7. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-131
8. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M,. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010; 58: 831-835
9. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190
10. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009; 55: 1-8
11. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP,. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer 2012; 118: 3512-3518
12. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre 'prostate cancer research international: active surveillance' study. BJU Int 2010; 105: 956-962
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374
14. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597-603
15. Parker C,. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-106
16. Liu D, Lehmann HP, Frick KD, Carter HB,. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol 2012; 187: 1241-1246
17. Fradet V, Kurhanewicz J, Cowan JE, et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010; 256: 176-183
18. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009; 56: 981-987
19. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ,. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110-1114
20. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM,. Complications after prostate biopsy: data from SEER-medicare. J Urol 2011; 186: 1830-1834
21. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952-955
22. Taylor AK, Zembower TR, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012; 187: 1275-1279
23. Wade J, Rosario DJ, Macefield RC, et al. Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol 2013; 31: 4235-4241
24. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M,. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007; 100: 540-543
25. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-2816
26. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011; 185: 1656-1660
27. Tosoian JJ, Loeb S, Kettermann A, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183: 534-538